Form 144 | Hims & Hers Health(HIMS.US) Officer Proposes to Sell 11.63 Million in Common Stocks
SEC FILLINGS DISCLOSED/ Sep 20, $Hims & Hers Health(HIMS.US)$ Officer Andrew Dudum intends to sell 687.5K shares of its common stock on Sep 20, with a total market value of approximately $11.63
Lilly Asks People Who Took Compounded Tirzepatide for Their Medical Records
Hims & Hers announced that they will offer a low stock price of the composite version Wegovy to specific professional groups in the USA.
Gelonghui September 19th | American remote medical services company Hims & Hers Health announced on Wednesday the launch of a new plan, offering a compounded version of Novo Nordisk's weight loss drug Wegovy at a discounted price of $99 per month to certain occupational patients. This pricing will be applicable to eligible US military personnel, teachers, nurses, police officers, firefighters, and veterans. According to its website, for patients participating in a 12-month treatment plan, the price of Semaglutide injectable solution is $199 per month. The company stated that the compounded GLP-1 injectable solution is developed by Hims &
Deep Dive Into Hims & Hers Health Stock: Analyst Perspectives (8 Ratings)
B of A Securities Maintains Buy on Hims & Hers Health, Lowers Price Target to $20
BofA Securities Maintains Hims & Hers Health(HIMS.US) With Buy Rating, Cuts Target Price to $20
BofA Securities analyst Allen Lutz maintains $Hims & Hers Health(HIMS.US)$ with a buy rating, and adjusts the target price from $24 to $20.According to TipRanks data, the analyst has a success rate